Early and accurate diagnosis of Alzheimer's disease remains crucial, especially with recent breakthroughs in treatments for ...

The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing ...

Despite its importance, problems related to CSF often go unnoticed until something goes wrong.

Researchers evaluated a fully automated plasma biomarker panel to detect early amyloid-β accumulation in cognitively unimpaired adults at risk for Alzheimer’s disease. Plasma p-tau217/Aβ42 emerged as ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

With more boost, more heat, and higher expectations, proper cooling is key — and CSF promises to deliver. In this video, we test intake air temps, driving behavior, and whether this upgrade ...

The FDA said 91.7% of those tested with the Fujirebio test had the presence of amyloid plaques shown by positron emission tomography (PET) scan or a cerebrospinal fluid (CSF) test result ...

Cerebrospinal fluid tests that compare the ratio of two proteins, pTau217 and beta-amyloid 1-42, can cut the need for PET scans, but the diagnostics rely on samples collected via a lumbar puncture.

Findings showed 91.7% of patients with positive results using Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test had amyloid plaques based on PET scan or CSF test results. The Food and Drug ...

Dr. Richard G. Stefanacci explains why the FDA's recent clearance of a diagnostic blood test for Alzheimer's deserves ...

A previous version of the Lumipulse G test obtained a de novo clearance in May 2022 for measuring two beta amyloid proteins in samples of cerebrospinal fluid taken via a spinal tap. Roche collects ...